Revision of Ireland’s Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs James F. O’Mahony Current Opinion Open access 27 July 2021 Pages: 339 - 348
National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison Deepshikha SharmaArun Kumar AggarwalShankar Prinja Review Article Open access 10 January 2021 Pages: 349 - 364
A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer Nan QiaoRalph InsingaMartin Sénécal Review Article Open access 19 January 2021 Pages: 365 - 383
High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? Wolfgang GreinerKeyur PatelTom Vandebrouck Review Article Open access 07 January 2021 Pages: 385 - 396
Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology Graeme BallMitch LevineJean-Eric Tarride Systematic Review Open access 24 April 2021 Pages: 397 - 410
State-Level Variations and Factors Associated with Adult Vaccination Coverage: A Multilevel Modeling Approach Diana GarbinskyShannon HunterCosmina Hogea Original Research Article Open access 16 April 2021 Pages: 411 - 423
The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease Dat T. TranDan PalfreyRobert Welsh Original Research Article Open access 23 January 2021 Pages: 425 - 435
Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan Kensuke MoriwakiSaki UechiKojiro Shimozuma Original Research Article Open access 23 January 2021 Pages: 437 - 447
Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement Taryn A. G. QuinlanBrock SchroederR. Brett McQueen Original Research Article Open access 10 March 2021 Pages: 449 - 458
Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis Hansoo KimGreg CookDanny Liew Original Research Article Open access 23 April 2021 Pages: 459 - 467
Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial Yoav GolanYuexin TangSanjeet Dadwal Original Research Article Open access 19 April 2021 Pages: 469 - 473
Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective Deirdre B. BlissettJoerg S. SteierRob S. Blissett Original Research Article Open access 28 April 2021 Pages: 475 - 489
Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, Canada Asif Raza KhowajaChristina KrauseCraig Mitton Original Research Article Open access 29 April 2021 Pages: 491 - 504
Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM) Meryl BrodMichael Højby RasmussenAristides Maniatis Original Research Article Open access 12 January 2021 Pages: 505 - 518
Economic Analysis of Transforaminal Lumbar Interbody Fusion Surgery Utilizing a Curved Bone Removal Device John H. PelozaMichael A. MillgramEly Ashkenazi Original Research Article Open access 19 January 2021 Pages: 519 - 531
Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study Cheli Melzer CohenNino HallénAvraham Karasik Original Research Article Open access 27 April 2021 Pages: 533 - 544
Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications Charles Ebuka Okafor Original Research Article Open access 07 January 2021 Pages: 545 - 557
Correction to: Introducing Rotavirus Vaccination in Nigeria: Economic Evaluation and Implications Charles Ebuka Okafor Correction Open access 09 February 2021 Pages: 559 - 559